Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines

Expression of RANKL/OPG during bone remodeling in vivo

(2011) H. Tanaka et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer Patients

(2011) Toni Ibrahim et al.   Clinical Breast Cancer

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

(2011) Daniele Santini et al.   PLoS One

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

(2010) Pamela M. Holland et al.   CANCER BIOLOGY & THERAPY

Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer

(2010) Lyndsay V. Rhodes et al.   CANCER RESEARCH

Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma

(2010) C.H. Buckle et al.   CURRENT PHARMACEUTICAL DESIGN

Proteoglycans on bone tumor development

(2010) Carmen Ruiz Velasco et al.   DRUG DISCOVERY TODAY

Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: Role in osteoclastogenesis and bone resorption

(2010) Marc Baud’huin et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo

(2010) Irene Zinonos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction

(2010) Mingzhu Huang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

CXCR4 and cancer

(2010) Bungo Furusato et al.   PATHOLOGY INTERNATIONAL

Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis

(2009) Takayuki Kobayashi et al.   BREAST CANCER RESEARCH AND TREATMENT

Invasion of Human Breast Cancer Cells In vivo Requires Both Paracrine and Autocrine Loops Involving the Colony-Stimulating Factor-1 Receptor

(2009) A. Patsialou et al.   CANCER RESEARCH

Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype

(2009) R. Romieu-Mourez et al.   JOURNAL OF IMMUNOLOGY

Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231

(2008) Vanessa Nicolin et al.   ACTA HISTOCHEMICA

Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?

(2008) A. Labrinidis et al.   BLOOD

Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway

(2008) Z Wang et al.   BRITISH JOURNAL OF CANCER

TRAIL and cancer therapy

(2008) Frank A.E. Kruyt   CANCER LETTERS

Role of full-length osteoprotegerin in tumor cell biology

(2008) G. Zauli et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Implications of the Cancer Stem-Cell Hypothesis for Breast Cancer Prevention and Therapy

(2008) Madhuri Kakarala et al.   JOURNAL OF CLINICAL ONCOLOGY

TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5

(2008) Y. Zhang et al.   MOLECULAR CANCER RESEARCH

Mesenchymal Stem Cells in Early Entry of Breast Cancer into Bone Marrow

(2008) Kelly E. Corcoran et al.   PLoS One